What is Pediatrix Medical Group, Inc.'s earnings per share (EPS)?

Pediatrix Medical Group, Inc. (MD) reported diluted earnings per share of $1.94 for fiscal year 2025. This represents a 263.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pediatrix Medical Group, Inc. (MD) Financials

Trailing 12 months to June 30, 2026

Revenue $2.0B +0.5% YoY

Net Income $174.8M +59.0% YoY

EPS (Diluted) $2.09 +60.8% YoY

Operating Cash Flow $246.9M +0.9% YoY

Market Cap $2.1B as of Oct 3, 2026

Price / Sales 1.1x on $2.0B revenue, trailing 12 months to June 30, 2026

Price / Earnings 12.1x on $174.8M net income, trailing 12 months to June 30, 2026

Price / Book 2.4x on $881.0M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MD SEC filings page.

Pediatrix Medical Group, Inc. (MD) reported $2.0B in revenue over the twelve months to Jun 30, 2026, up 0.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MD FY2025 2026-10-04

Operating profitability was restored in FY2025 while revenue stayed near $1.9B and leverage eased.

FY2025 revenue remained near $1.9B, while operating margin recovered to 10.9% from a loss-making FY2024, making this a profitability reset rather than volume-led expansion. That recovery was accompanied by operating cash flow of $271.1M versus net income of $165.4M, so cash conversion exceeded accounting profit; receivables also fell from $260.0M to $229.7M, indicating working-capital release supported the cash result.

The 1.1x-to-0.7x decline in debt-to-equity from FY2021 to FY2025 shows lower balance-sheet leverage, not merely a better profit year. A 1.7x current ratio and $865.9M of equity indicate improved short-term coverage and a rebuilt capital base, although debt remains part of the structure.

Revenue slipped to $1.9B in FY2025, yet operating income reached $208.8M; the turnaround therefore came from profitability mechanics below the top line, not broad expansion. The reported pattern is consistent with changes in costs, operating items, or revenue mix rather than a larger business footprint.

Financial Health Signals

Financial Health Score 35/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Pediatrix Medical Group, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Pediatrix Medical Group, Inc. has an operating margin of 10.9%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 45/100, indicating healthy but not exceptional operating efficiency. This is up from -3.4% the prior year.

Growth

Pediatrix Medical Group, Inc.'s revenue declined 4.9% year-over-year, from $2.0B to $1.9B. This contraction results in a growth score of 23/100.

Leverage

Pediatrix Medical Group, Inc. has a moderate D/E ratio of 0.66. This balance of debt and equity financing earns a leverage score of 51/100.

Liquidity

Pediatrix Medical Group, Inc.'s current ratio of 1.66 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Not available for Pediatrix Medical Group, Inc., and counted as zero in the overall score.

Returns

Pediatrix Medical Group, Inc.'s ROE of 19.1% shows moderate profitability relative to equity, earning a score of 42/100. This is up from -13.0% the prior year.

Altman Z-Score Grey Zone

2.19

Pediatrix Medical Group, Inc. scores 2.19, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

7/8

Pediatrix Medical Group, Inc. passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.64x

For every $1 of reported earnings, Pediatrix Medical Group, Inc. generates $1.64 in operating cash flow ($271.1M OCF vs $165.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.81x

Pediatrix Medical Group, Inc. earns $5.81 in operating income for every $1 of interest expense ($208.8M vs $36.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$487.8M

YoY+4.0%

QoQ+2.4%

5Y CAGR+0.6%

Pediatrix Medical Group, Inc. generated $487.8M in revenue in Q2 2026. This represents an increase of 4.0% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.

EBITDA

$62.7M

YoY-3.8%

QoQ+31.2%

5Y CAGR+1.5%

10Y CAGR-9.4%

Pediatrix Medical Group, Inc.'s EBITDA was $62.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.8% from the same quarter a year earlier. Against the prior quarter it is up 31.2%.

Net Income

$39.8M

YoY+1.5%

QoQ+34.7%

5Y CAGR+2.6%

10Y CAGR-7.0%

Pediatrix Medical Group, Inc. reported $39.8M in net income in Q2 2026. This represents an increase of 1.5% from the same quarter a year earlier. Against the prior quarter it is up 34.7%.

EPS (Diluted)

$0.49

YoY+6.5%

QoQ+36.1%

5Y CAGR+3.6%

10Y CAGR-5.8%

Pediatrix Medical Group, Inc. earned $0.49 per diluted share (EPS) in Q2 2026. This represents an increase of 6.5% from the same quarter a year earlier. Against the prior quarter it is up 36.1%.

Cash & Balance Sheet

Cash & Debt

$288.9M

YoY+28.5%

QoQ+40.4%

5Y CAGR-3.1%

10Y CAGR+18.7%

Pediatrix Medical Group, Inc. held $288.9M in cash against $398.1M in long-term debt as of Q2 2026.

Shares Outstanding

81M

YoY-6.7%

QoQ-1.1%

5Y CAGR-1.2%

10Y CAGR-1.4%

Pediatrix Medical Group, Inc. had 81M shares outstanding in Q2 2026. This represents a decrease of 6.7% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

11.7%

YoY-1.1pp

QoQ+2.9pp

5Y change+1.1pp

Pediatrix Medical Group, Inc.'s operating margin was 11.7% in Q2 2026, reflecting core business profitability. This is down 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.9 percentage points.

Net Margin

8.2%

YoY-0.2pp

QoQ+2.0pp

5Y change+0.8pp

Pediatrix Medical Group, Inc.'s net profit margin was 8.2% in Q2 2026, showing the share of revenue converted to profit. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.

Return on Equity

4.5%

YoY-0.2pp

QoQ+1.1pp

5Y change+0.2pp

10Y change+1.3pp

Pediatrix Medical Group, Inc.'s ROE was 4.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

Share Buybacks

$42.7M

YoY+20351.7%

QoQ+99.3%

5Y CAGR+179.4%

Pediatrix Medical Group, Inc. spent $42.7M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 20351.7% from the same quarter a year earlier. Against the prior quarter it is up 99.3%.

R&D Spending

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

MD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MD quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$2.0B	$1.9B-4.9%	$2.0B+0.9%	$2.0B+1.1%	$2.0B+3.2%	$1.9B+10.2%	$1.7B-2.6%	$1.8B+3.3%	$1.7B-47.0%	$3.3B+2.2%	$3.2B	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$248.0M	$240.8M+1.0%	$238.4M+4.8%	$227.5M-1.7%	$231.4M-12.1%	$263.4M+5.8%	$248.9M+1.8%	$244.5M+5.3%	$232.2M-39.8%	$385.9M+3.6%	$372.6M+21.8%	$305.9M+23.6%	$247.5M+13.4%	$218.2M+12.7%	$193.5M+13.6%	$170.4M
Operating Income	$215.4M	$208.8M+403.9%	-$68.7M-1038.6%	$7.3M-95.8%	$172.7M-14.9%	$202.9M+106.8%	$98.1M-42.9%	$171.8M-30.9%	$248.4M-45.4%	$454.9M-20.4%	$571.7M+2.5%	$557.9M+8.7%	$513.0M+13.5%	$452.1M+16.1%	$389.5M+9.6%	$355.4M
EBITDA	N/A	$230.6M+732.1%	-$36.5M-183.9%	$43.5M-79.1%	$208.3M-11.4%	$235.1M+85.7%	$126.6M-36.0%	$197.7M-27.5%	$272.7M-48.9%	$533.7M-19.2%	$661.0M+6.2%	$622.1M+11.3%	$559.0M+13.6%	$492.1M+17.1%	$420.3M+10.4%	$380.7M
Interest Expense	$34.1M	$36.0M-11.7%	$40.7M-3.2%	$42.1M+6.0%	$39.7M-42.2%	$68.7M-37.8%	$110.5M-7.1%	$118.9M+28.0%	$92.9M+24.7%	$74.6M+18.2%	$63.1M+173.0%	$23.1M+159.9%	$8.9M+64.2%	$5.4M+66.9%	$3.2M-10.8%	$3.6M
Income Tax	$51.4M	$51.0M+2346.7%	-$2.3M-118.9%	$12.0M-35.9%	$18.8M-31.0%	$27.2M+62.8%	$16.7M+0.9%	$16.6M-62.9%	$44.7M-44.3%	$80.2M-57.6%	$189.2M-7.3%	$204.0M+6.6%	$191.4M+14.0%	$167.9M+14.0%	$147.3M+8.9%	$135.2M
Net Income	$174.8M	$165.4M+266.9%	-$99.1M-64.0%	-$60.4M-191.1%	$66.3M-49.3%	$131.0M+116.4%	-$796.5M+46.8%	-$1.5B-657.5%	$268.6M-16.2%	$320.4M-1.4%	$324.9M-3.4%	$336.3M+6.0%	$317.3M+13.1%	$280.5M+16.4%	$240.9M+10.5%	$218.0M
EPS (Basic)	N/A	$1.97+265.5%	-$1.19-63.0%	-$0.73-192.4%	$0.79-48.7%	$1.54+116.1%	-$9.55+46.8%	-$17.94-708.1%	$2.95-15.0%	$3.47-1.4%	$3.52-2.5%	$3.61+12.1%	$3.22+13.8%	$2.83+14.6%	$2.47+8.3%	$2.28
EPS (Diluted)	$2.09	$1.94+263.0%	-$1.19-63.0%	-$0.73-192.4%	$0.79-48.4%	$1.53+116.0%	-$9.55+46.4%	-$17.83-708.5%	$2.93-15.1%	$3.45-1.1%	$3.49-2.5%	$3.58+12.6%	$3.18+14.4%	$2.78	$2.42+8.5%	$2.23
Diluted Shares (Avg)	N/A	85M+2.5%	83M+1.4%	82M-2.3%	84M-2.0%	86M+2.9%	83M-0.7%	84M-8.3%	92M-1.5%	93M-0.2%	93M-0.9%	94M-5.9%	100M-1.1%	101M	99M+1.8%	98M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$487.8M+4.0%	$476.2M+3.9%	$493.8M-1.7%	$492.9M-3.6%	$468.8M-7.0%	$458.4M-7.4%	$502.4M+1.2%	$511.2M+0.9%
SG&A Expenses	$61.3M+10.0%	$60.3M+2.8%	$65.7M+3.3%	$60.8M+4.6%	$55.7M-1.5%	$58.6M-2.6%	$63.6M+19.8%	$58.1M+1.2%
Operating Income	$56.9M-4.9%	$41.7M+29.8%	$48.8M+24.2%	$68.1M+101.2%	$59.9M+138.0%	$32.1M+102.0%	$39.3M+135.2%	$33.8M-16.0%
EBITDA	$62.7M-3.8%	$47.8M+27.6%	$54.4M+17.9%	$73.6M+83.6%	$65.2M+143.8%	$37.4M+42.9%	$46.2M+145.1%	$40.1M-19.0%
Interest Expense	$8.2M-10.5%	$8.3M-9.7%	$8.7M-10.0%	$8.9M-11.7%	$9.1M-11.4%	$9.2M-13.6%	$9.7M-3.7%	$10.1M-2.4%
Income Tax	$14.2M-9.9%	$9.3M+26.1%	$11.9M+318.3%	$16.1M+177.4%	$15.7M+206.8%	$7.4M+94.1%	$2.8M+119.6%	$5.8M-38.6%
Net Income	$39.8M+1.5%	$29.6M+42.6%	$33.7M+10.5%	$71.7M+268.8%	$39.3M+125.7%	$20.7M+413.9%	$30.5M+124.5%	$19.4M-9.1%
EPS (Basic)	$0.50+8.7%	$0.37+48.0%	$0.41+10.8%	$0.85+269.6%	$0.46+125.0%	$0.25+400.0%	$0.37+840.0%	$0.23-11.5%
EPS (Diluted)	$0.49+6.5%	$0.36+50.0%	$0.40+8.1%	$0.84+265.2%	$0.46+125.0%	$0.24+380.0%	$0.37	$0.23-11.5%
Diluted Shares (Avg)	81M-4.8%	83M-2.8%	N/A	86M+1.3%	86M+2.6%	85M+2.6%	N/A	85M+1.9%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

MD Balance Sheet

MD quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$2.2B+4.4%	$2.2B-3.0%	$2.2B-5.5%	$2.3B-13.8%	$2.7B-18.7%	$3.3B-19.2%	$4.1B-30.2%	$5.9B+1.2%	$5.9B+9.9%	$5.3B+17.4%	$4.5B+26.0%	$3.6B+19.9%	$3.0B+9.4%	$2.8B+21.0%	$2.3B
Current Assets	$763.5M+19.4%	$639.6M+32.3%	$483.5M+13.0%	$428.0M-49.1%	$840.6M-45.7%	$1.5B+111.8%	$731.5M+10.8%	$660.0M+5.2%	$627.2M+6.8%	$587.1M+11.2%	$527.8M+13.0%	$467.1M+26.9%	$368.1M+2.5%	$359.0M+6.5%	$337.3M
Cash & Equivalents	$375.2M+63.2%	$229.9M+213.9%	$73.3M+645.7%	$9.8M-97.5%	$387.4M-65.5%	$1.1B+941.8%	$107.9M+164.6%	$40.8M+0.8%	$40.4M-27.4%	$55.7M+8.0%	$51.6M+7.6%	$47.9M+53.9%	$31.1M+46.3%	$21.3M+14.4%	$18.6M
Short-Term Investments	$124.5M+5.0%	$118.6M+13.5%	$104.5M+12.1%	$93.2M-6.5%	$99.7M-4.9%	$104.9M	$0-100.0%	$21.9M+113.0%	$10.3M-8.8%	$11.3M+27.5%	$8.9M+46.7%	$6.0M-6.5%	$6.5M-1.9%	$6.6M+59.1%	$4.1M
Accounts Receivable	$229.7M-11.7%	$260.0M-4.5%	$272.3M-8.2%	$296.8M-1.7%	$301.8M+24.7%	$241.9M-44.3%	$434.3M-14.3%	$506.7M+0.5%	$504.0M+1.8%	$495.3M+11.4%	$444.7M+26.3%	$352.2M+23.4%	$285.4M+15.0%	$248.1M+7.7%	$230.4M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$69.7M-13.6%	$80.7M+2.2%	$79.0M+24.8%	$63.3M-1.2%	$64.1M+11.4%	$57.5M+20.8%	$47.6M+5.8%	$45.0M
Goodwill	$1.3B+1.5%	$1.2B-10.2%	$1.4B-9.7%	$1.5B+1.8%	$1.5B+1.9%	$1.5B-0.1%	$1.5B-63.6%	$4.1B-5.2%	$4.3B+11.4%	$3.8B+14.2%	$3.4B+21.3%	$2.8B+16.0%	$2.4B+10.5%	$2.2B+24.0%	$1.7B
Total Liabilities	$1.4B-0.5%	$1.4B+1.2%	$1.4B-5.9%	$1.5B-20.2%	$1.8B-29.8%	$2.6B-1.8%	$2.6B-7.1%	$2.8B+1.7%	$2.8B+8.6%	$2.6B+22.2%	$2.1B+57.1%	$1.3B+101.7%	$665.7M-6.9%	$715.0M+32.0%	$541.6M
Current Liabilities	$458.9M+5.7%	$434.1M+11.6%	$388.9M-8.9%	$427.0M-0.1%	$427.4M-3.8%	$444.3M-18.0%	$541.8M+7.8%	$502.8M-5.4%	$531.4M+18.4%	$448.9M+4.7%	$428.8M+3.0%	$416.3M+27.4%	$326.8M+21.8%	$268.3M+5.5%	$254.3M
Non-Current Liabilities	$921.9M-3.3%	$953.7M-2.9%	$981.8M-4.6%	$1.0B-26.4%	$1.4B-35.1%	$2.2B+2.4%	$2.1B-10.3%	$2.3B+3.4%	$2.3B+6.6%	$2.1B+26.7%	$1.7B+81.4%	$926.4M+173.3%	$338.9M-24.1%	$446.6M+55.4%	$287.3M
Long-Term Debt	$570.5M-4.5%	$597.1M-3.4%	$618.4M-2.2%	$632.4M-36.1%	$989.7M-41.8%	$1.7B0.0%	$1.7B-13.7%	$2.0B+6.7%	$1.8B+10.0%	$1.7B+33.2%	$1.3B+126.1%	$557.5M+1964.6%	$27.0M	N/A	N/A
Total Equity	$865.9M+13.2%	$764.9M-9.9%	$849.1M-4.8%	$891.6M-0.5%	$896.5M+19.9%	$747.5M-50.1%	$1.5B-51.5%	$3.1B+0.7%	$3.1B+11.1%	$2.8B+13.3%	$2.4B+7.6%	$2.3B-3.3%	$2.3B+15.1%	$2.0B+17.6%	$1.7B
Retained Earnings	-$83.2M+66.5%	-$248.5M-66.3%	-$149.5M-67.8%	-$89.1M+42.7%	-$155.4M+45.7%	-$286.4M-156.1%	$510.1M-75.6%	$2.1B+2.3%	$2.0B+14.7%	$1.8B+18.2%	$1.5B+9.7%	$1.4B-7.2%	$1.5B+19.0%	$1.2B+23.9%	$1.0B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$2.1B+1.3%	$2.1B+3.9%	$2.2B+4.4%	$2.2B+5.9%	$2.1B+5.3%	$2.0B-8.1%	$2.2B-3.0%	$2.1B-10.7%
Current Assets	$660.1M+7.7%	$587.0M+19.4%	$763.5M+19.4%	$717.2M+35.8%	$613.0M+42.8%	$491.7M+15.3%	$639.6M+32.3%	$528.2M+25.6%
Cash & Equivalents	$288.9M+28.5%	$205.8M+107.9%	$375.2M+63.2%	$340.1M+227.5%	$224.7M+1058.3%	$99.0M+1137.5%	$229.9M+213.9%	$103.8M+390.3%
Short-Term Investments	$115.3M-6.7%	$123.2M+2.5%	$124.5M+5.0%	$123.0M+5.5%	$123.6M+8.6%	$120.2M+11.8%	$118.6M+13.5%	$116.6M+12.6%
Accounts Receivable	$227.6M-4.8%	$224.8M-7.3%	$229.7M-11.7%	$231.1M-19.4%	$239.0M-12.8%	$242.5M-14.5%	$260.0M-4.5%	$286.9M+3.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.3B+2.1%	$1.3B+2.1%	$1.3B+1.5%	$1.3B+1.3%	$1.2B+0.3%	$1.2B-10.8%	$1.2B-10.2%	$1.2B-19.1%
Total Liabilities	$1.2B-1.5%	$1.2B-1.0%	$1.4B-0.5%	$1.3B-2.7%	$1.3B-1.6%	$1.2B-8.2%	$1.4B+1.2%	$1.3B-1.0%
Current Liabilities	$501.6M+47.1%	$442.6M+63.3%	$458.9M+5.7%	$392.5M+5.2%	$341.0M+10.0%	$271.1M+9.6%	$434.1M+11.6%	$373.1M+6.5%
Non-Current Liabilities	$747.8M-19.4%	$749.1M-19.7%	$921.9M-3.3%	$916.2M-5.7%	$927.3M-5.3%	$933.2M-12.3%	$953.7M-2.9%	$971.3M-3.6%
Long-Term Debt	$398.1M-31.8%	$398.3M-32.5%	$570.5M-4.5%	$577.2M	$583.9M	$590.5M	$597.1M-3.4%	N/A
Total Equity	$881.0M+5.7%	$878.6M+11.3%	$865.9M+13.2%	$890.7M+21.6%	$833.8M+18.0%	$789.2M-7.8%	$764.9M-9.9%	$732.5M-24.3%
Retained Earnings	-$13.7M+92.7%	-$53.6M+76.5%	-$83.2M+66.5%	-$116.8M+58.1%	-$188.5M+36.8%	-$227.8M-56.6%	-$248.5M-66.3%	-$279.0M-1007.9%

Not reported in any period shown, so not listed: Inventory.

MD Cash Flow Statement

MD quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$246.9M	$271.1M+31.2%	$206.6M+50.4%	$137.3M-17.7%	$166.9M+117.5%	$76.7M-62.5%	$204.6M-42.8%	$357.7M+14.0%	$313.7M-38.7%	$511.4M+15.2%	$443.8M+20.4%	$368.7M-12.8%	$422.6M+4.3%	$405.4M+24.8%	$324.9M+20.0%	$270.7M
Depreciation & Amortization	N/A	$21.8M-32.3%	$32.2M-10.9%	$36.2M+1.5%	$35.6M+10.9%	$32.1M+13.0%	$28.4M+9.7%	$25.9M+6.5%	$24.4M-69.1%	$78.9M-11.7%	$89.3M+39.0%	$64.2M+39.7%	$46.0M+15.1%	$40.0M+29.7%	$30.8M+21.8%	$25.3M
Stock-Based Compensation	N/A	$18.0M+52.0%	$11.9M-3.7%	$12.3M-23.6%	$16.1M-15.0%	$19.0M-51.4%	$39.0M+16.9%	$33.4M-8.7%	$36.6M+27.1%	$28.8M-15.4%	$34.0M+5.8%	$32.1M+1.3%	$31.7M+1.4%	$31.3M+10.0%	$28.4M+5.0%	$27.1M
Investing Cash Flow	-$9.6M	-$18.3M+48.3%	-$35.4M+26.5%	-$48.2M+15.4%	-$57.0M-7.3%	-$53.1M-106.5%	$815.5M+696.0%	$102.5M+171.8%	-$142.8M+75.2%	-$576.6M+29.8%	-$821.2M	N/A	N/A	-$263.5M+42.8%	-$460.5M-141.7%	-$190.6M
Financing Cash Flow	-$173.1M	-$107.5M-642.1%	-$14.5M+43.7%	-$25.7M+94.7%	-$487.6M+35.9%	-$760.1M-18180.8%	-$4.2M+98.9%	-$393.1M-130.4%	-$170.6M-290.1%	$89.7M-76.5%	$381.6M	N/A	N/A	-$132.1M-195.5%	$138.3M+257.6%	-$87.8M
Share Buybacks	$149.1M	$86.7M+4990.0%	$1.7M+85.3%	$919K-99.0%	$88.5M+1775.6%	$4.7M-44.4%	$8.5M-94.2%	$145.3M-51.9%	$302.2M+330.5%	$70.2M+13.5%	$61.8M-73.7%	$235.1M-51.9%	$488.4M+841.8%	$51.9M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$125.3M-8.6%	-$129.8M-10.5%	$114.1M-14.2%	$137.3M+49.5%	$137.2M+28.3%	-$117.5M+6.2%	$133.0M+92.1%	$91.8M+14.9%
Depreciation & Amortization	$5.8M+8.8%	$6.1M+14.8%	$5.6M-18.1%	$5.6M-11.2%	$5.3M-39.6%	$5.3M-48.3%	$6.9M-24.2%	$6.3M-32.1%
Stock-Based Compensation	N/A	$4.7M+28.0%	N/A	$3.4M+30.8%	$2.0M0.0%	$3.6M+18.7%	N/A	$2.6M-18.8%
Investing Cash Flow	$6.0M+184.1%	-$12.0M-60.5%	-$10.3M-430.5%	$6.6M+252.2%	-$7.2M+44.5%	-$7.5M+54.0%	-$1.9M+84.4%	-$4.3M+69.0%
Financing Cash Flow	-$48.2M-1032.7%	-$27.6M-357.9%	-$68.6M-1283.0%	-$28.6M-830.1%	-$4.3M+94.8%	-$6.0M-107.9%	-$5.0M-4.6%	-$3.1M+93.9%
Share Buybacks	$42.7M+20351.7%	$21.5M+1267.2%	$64.0M+9859.3%	$20.9M+12780.9%	$209K+1800.0%	$1.6M+76.9%	$643K	$162K+21.8%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

MD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MD quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	10.9%+14.3pp	-3.4%-3.8pp	0.4%-8.4pp	8.8%-1.9pp	10.6%+5.0pp	5.7%-4.0pp	9.7%-4.8pp	14.4%+0.4pp	14.0%-4.0pp	18.0%	N/A	N/A	N/A	N/A	N/A
Net Margin	8.6%+13.6pp	-4.9%-1.9pp	-3.0%-6.4pp	3.4%-3.5pp	6.9%+52.8pp	-45.9%+38.2pp	-84.2%-99.7pp	15.6%+5.7pp	9.8%-0.4pp	10.2%	N/A	N/A	N/A	N/A	N/A
Return on Equity	19.1%+32.0pp	-13.0%-5.8pp	-7.1%-14.5pp	7.4%-7.2pp	14.6%+121.2pp	-106.6%-6.7pp	-99.9%-108.6pp	8.7%-1.8pp	10.4%-1.3pp	11.8%-2.0pp	13.8%-0.2pp	14.0%+2.0pp	12.0%+0.1pp	11.8%-0.8pp	12.6%
Return on Assets	7.4%+12.0pp	-4.6%-1.9pp	-2.7%-5.5pp	2.8%-2.0pp	4.8%+28.6pp	-23.8%+12.3pp	-36.1%-40.6pp	4.5%-0.9pp	5.5%-0.6pp	6.1%-1.3pp	7.4%-1.4pp	8.8%-0.5pp	9.3%+0.6pp	8.8%-0.8pp	9.6%
Current Ratio	1.66+0.2x	1.47+0.2x	1.24+0.2x	1.00-1.0x	1.97-1.5x	3.49+2.1x	1.350.0x	1.31+0.1x	1.18-0.1x	1.31+0.1x	1.23+0.1x	1.120.0x	1.13-0.2x	1.340.0x	1.33
Debt-to-Equity	0.66-0.1x	0.78+0.1x	0.730.0x	0.71-0.4x	1.10-1.2x	2.27+1.1x	1.13+0.5x	0.640.0x	0.600.0x	0.61+0.1x	0.52+0.3x	0.25+0.2x	0.01-0.3x	0.350.0x	0.31
Asset Turnover	0.85-0.1x	0.940.0x	0.90+0.1x	0.84+0.1x	0.70+0.2x	0.52+0.1x	0.43+0.1x	0.29-0.3x	0.550.0x	0.60	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	11.7%-1.1pp	8.8%+1.7pp	9.9%+2.1pp	13.8%+7.2pp	12.8%+44.0pp	7.0%+3.8pp	7.8%+30.3pp	6.6%-1.3pp
Net Margin	8.2%-0.2pp	6.2%+1.7pp	6.8%+0.8pp	14.5%+10.7pp	8.4%+38.7pp	4.5%+3.7pp	6.1%+31.1pp	3.8%-0.4pp
Return on Equity	4.5%-0.2pp	3.4%+0.7pp	3.9%-0.1pp	8.1%+5.4pp	4.7%+26.4pp	2.6%+2.2pp	4.0%+18.6pp	2.6%+0.4pp
Return on Assets	1.9%0.0pp	1.4%+0.4pp	1.5%+0.1pp	3.3%+2.3pp	1.9%+9.5pp	1.0%+0.8pp	1.4%+7.0pp	0.9%0.0pp
Current Ratio	1.32-0.5x	1.33-0.5x	1.66+0.2x	1.83+0.4x	1.80+0.4x	1.81+0.1x	1.47+0.2x	1.42+0.2x
Debt-to-Equity	0.45-0.2x	0.45-0.3x	0.66-0.1x	0.65-1.2x	0.70-1.1x	0.75-0.8x	0.78+0.1x	1.84+1.2x
Asset Turnover	0.230.0x	0.230.0x	0.220.0x	0.220.0x	0.220.0x	0.230.0x	0.230.0x	0.250.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Pediatrix Medical Group, Inc. MD	FY2025	$1.9B	$165.4M	8.6%	$2.1B	35/100
SELECT MEDICAL HOLDINGS CORP SEM	FY2025	$5.5B	$146.2M	2.7%	$2.0B	40/100
PACS Group, Inc. PACS	FY2025	$5.3B	$191.5M	3.6%	$6.8B	49/100
Astrana Health Inc. ASTH	FY2025	$3.2B	$24.0M	0.8%	$1.8B	49/100
Aveanna Healthcare Holdings Inc. AVAH	FY2026	$2.4B	$225K	0.0%	$2.7B	36/100
Guardian Pharmacy Services, Inc. GRDN	FY2025	$1.4B	$49.2M	3.4%	$2.7B	53/100

Where Pediatrix Medical Group, Inc. Ranks

Frequently Asked Questions

What is Pediatrix Medical Group, Inc.'s annual revenue?

Pediatrix Medical Group, Inc. (MD) reported $1.9B in total revenue for fiscal year 2025. This represents a -4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Pediatrix Medical Group, Inc.'s revenue growing?

Pediatrix Medical Group, Inc. (MD) revenue declined by 4.9% year-over-year, from $2.0B to $1.9B in fiscal year 2025.

Is Pediatrix Medical Group, Inc. profitable?

Yes, Pediatrix Medical Group, Inc. (MD) reported a net income of $165.4M in fiscal year 2025, with a net profit margin of 8.6%.

What is Pediatrix Medical Group, Inc.'s EBITDA?

Pediatrix Medical Group, Inc. (MD) had EBITDA of $230.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Pediatrix Medical Group, Inc. have?

As of fiscal year 2025, Pediatrix Medical Group, Inc. (MD) had $375.2M in cash and equivalents against $570.5M in long-term debt.

What is Pediatrix Medical Group, Inc.'s operating margin?

Pediatrix Medical Group, Inc. (MD) had an operating margin of 10.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Pediatrix Medical Group, Inc.'s net profit margin?

Pediatrix Medical Group, Inc. (MD) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Pediatrix Medical Group, Inc.'s return on equity (ROE)?

Pediatrix Medical Group, Inc. (MD) has a return on equity of 19.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pediatrix Medical Group, Inc.'s operating cash flow?

Pediatrix Medical Group, Inc. (MD) generated $271.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pediatrix Medical Group, Inc.'s total assets?

Pediatrix Medical Group, Inc. (MD) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.

Does Pediatrix Medical Group, Inc. buy back shares?

Yes, Pediatrix Medical Group, Inc. (MD) spent $86.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Pediatrix Medical Group, Inc. have outstanding?

Pediatrix Medical Group, Inc. (MD) had 83M shares outstanding as of fiscal year 2025.

What is Pediatrix Medical Group, Inc.'s current ratio?

Pediatrix Medical Group, Inc. (MD) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.

What is Pediatrix Medical Group, Inc.'s debt-to-equity ratio?

Pediatrix Medical Group, Inc. (MD) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pediatrix Medical Group, Inc.'s return on assets (ROA)?

Pediatrix Medical Group, Inc. (MD) had a return on assets of 7.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pediatrix Medical Group, Inc.'s P/E ratio?

Pediatrix Medical Group, Inc. (MD) trades at 12.1x earnings, its market capitalization divided by net income of $174.8M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.1B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Pediatrix Medical Group, Inc.'s price-to-sales ratio?

Pediatrix Medical Group, Inc. (MD) trades at 1.1x sales, its market capitalization divided by revenue of $2.0B revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.1B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Pediatrix Medical Group, Inc.'s Altman Z-Score?

Pediatrix Medical Group, Inc. (MD) has an Altman Z-Score of 2.19, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Pediatrix Medical Group, Inc.'s Piotroski F-Score?

Pediatrix Medical Group, Inc. (MD) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pediatrix Medical Group, Inc.'s earnings high quality?

Pediatrix Medical Group, Inc. (MD) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pediatrix Medical Group, Inc. cover its interest payments?

Pediatrix Medical Group, Inc. (MD) has an interest coverage ratio of 5.81x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Pediatrix Medical Group, Inc.?

Pediatrix Medical Group, Inc. (MD) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.